Free Access
Med Sci (Paris)
Volume 21, Number 10, Octobre 2005
Page(s) 797 - 798
Section Nouvelles
Published online 15 October 2005
  1. Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab : unforeseen consequences. N Engl J Med 2005; 353 : 414–6. [Google Scholar]
  2. Langer-Gould A, Atlas SW, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353 : 375–81. [Google Scholar]
  3. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 2005; 353 : 362–8. [Google Scholar]
  4. Kleinschmidt-Demasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353 : 369–74. [Google Scholar]
  5. Dubois V, Moret H, Lafon ME, et al. JC virus genotypes in France: molecular epidemiology and potential significance for progressive multifocal leukoencephalopathy. J Infect Dis 2001; 183 : 213–7. [Google Scholar]
  6. Von Andrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003; 348 : 68–72. [Google Scholar]
  7. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn’s disease. N Engl J Med 2003; 348 : 24–32. [Google Scholar]
  8. Rice GP, Hartung HP, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005; 64 : 1336–42. [Google Scholar]
  9. Goldberg SL, Pecora AL, Alter RS, et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002; 99 : 1486–8. [Google Scholar]
  10. Imperato AK, Bingham CO 3rd, Abramson SB. Overview of benefit/risk of biological agents. Clin Exp Rheumatol 2004; 22 : S108–14. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.